Investigation Confirmed the Chromosomal Abnormality in a Single Patient was Not Observed in Any AlloCAR T Product and Not Related to Allogene Manufacturing Process or TALEN® Gene Editing
Clinical Trials Across the AlloCAR T Platform to Resume
Pivotal Phase 2 Trial of ALLO-501A in Relapsed/Refractory Large B Cell Lymphoma Expected to Commence in Mid-Year 2022 Pending FDA Discussions
Company to Host Conference Call Today at 8:30 am PT/11:30 am ET
Conference Call and Webcast Details
Allogene will host a live conference call and webcast today at 8:30 a.m. Pacific Time / 11:30 a.m. Eastern Time to provide a business update. To access the live conference call by telephone, please dial 1 (866) 940-5062 (U.S.) or 1 (409) 216-0618 (International). The conference ID number for the live call is 8598466. The webcast will be made available on the Company's website at www.allogene.com under the Investors tab in the News and Events section. Following the live audio webcast, a replay will be available on the Company's website for approximately 30 days.
Allogene will host a live conference call and webcast today at 8:30 a.m. Pacific Time / 11:30 a.m. Eastern Time to provide a business update. To access the live conference call by telephone, please dial 1 (866) 940-5062 (U.S.) or 1 (409) 216-0618 (International). The conference ID number for the live call is 8598466. The webcast will be made available on the Company's website at www.allogene.com under the Investors tab in the News and Events section. Following the live audio webcast, a replay will be available on the Company's website for approximately 30 days.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.